CoChat
Sign Up
Cited by 67

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Leptin and insulin down-regulate angiopoietin-like protein 3, a plasma triglyceride-increasing factor

Shimamura, Mitsuru, Matsuda, Morihiro, Ando, Yosuke, Koishi, Ryuta, Yasumo, Hiroaki, Furukawa, Hidehiko, Shimomura, Iichiro·2004·Biochemical and Biophysical Research Communications
DOI 10.1016/j.bbrc.2004.08.024
Open this paper in CoChat — free account

Abstract

We reported previously that angiopoietin-like protein3 (ANGPTL3), a liver-specific secretory factor, increased plasma triglyceride (TG) via inhibition of lipoprotein lipase and free fatty acid (FFA) by activating adipose-lipolysis. The current study examined the regulation of Angptl3 by leptin and insulin, both of which are key players in the metabolic syndrome. Angptl3 expression and plasma ANGPTL3 levels were increased in leptin-resistant C57BL/6J(db/db) and -deficient C57BL/6J(ob/ob) mice, relative to the control. Leptin supplements decreased Angptl3 gene expression and plasma ANGPTL3 in C57BL/6J(ob/ob) mice. The changes of Angptl3 were associated with alterations of plasma TG and FFA levels. Leptin treatment directly suppressed Angptl3 gene expression in hepatocytes. Angptl3 gene expression and plasma protein levels were also increased in insulin-deficient streptozotocin-treated mice. Insulin treatment of hepatocytes decreased Angptl3 gene expression and protein secretion. Our results suggest that elevated ANGPTL3 by leptin- or insulin-resistance is attributed to increased plasma TG and FFA concentrations in obesity.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.bbrc.2004.08.024

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 25

  1. Cullen, 2000, Evidence that triglycerides are an independent coronary heart disease risk factor, Am. J. Cardiol., 86, 943, 10.1016/S0002-9149(00)01127-9 · DOI
  2. Reaven, 2002, Multiple CHD risk factors in type 2 diabetes: beyond hyperglycemia, Diabetes Obes. Metab., 4, S13, 10.1046/j.1462-8902.2001.00037.x · DOI
  3. Ginsberg, 2000, Insulin resistance and cardiovascular disease, J. Clin. Invest., 106, 453, 10.1172/JCI10762 · DOI
  4. Egger, 1999, Triglyceride as a risk factor for ischaemic heart disease in British men: effect of adjusting for measurement error, Atherosclerosis, 143, 275, 10.1016/S0021-9150(98)00300-1 · DOI
  5. Ross, 1993, The pathogenesis of atherosclerosis: a perspective for the 1990s, Nature, 362, 801, 10.1038/362801a0 · DOI
  6. Stiko-Rahm, 1990, Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein, Arteriosclerosis, 10, 1067, 10.1161/01.ATV.10.6.1067 · DOI
  7. Nagy, 1998, Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma, Cell, 93, 229, 10.1016/S0092-8674(00)81574-3 · DOI
  8. Kawakami, 2003, Remnant lipoprotein-induced smooth muscle cell proliferation involves epidermal growth factor receptor transactivation, Circulation, 108, 2679, 10.1161/01.CIR.0000093278.75565.87 · DOI
  9. Teno, 2000, Association of postprandial hypertriglyceridemia and carotid intima-media thickness in patients with type 2 diabetes, Diabetes Care, 23, 1401, 10.2337/diacare.23.9.1401 · DOI
  10. Roche, 2000, The impact of postprandial lipemia in accelerating atherothrombosis, J. Cardiovasc. Risk, 7, 317
  11. Koishi, 2002, Angptl3 regulates lipid metabolism in mice, Nat. Genet., 30, 151, 10.1038/ng814 · DOI · Paper page
  12. Camenisch, 2002, ANGPTL3 stimulates endothelial cell adhesion and migration via integrin alpha v beta 3 and induces blood vessel formation in vivo, J. Biol. Chem., 277, 17281, 10.1074/jbc.M109768200 · DOI
  13. Shimizugawa, 2002, ANGPTL3 decreases very low-density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase, J. Biol. Chem., 277, 33742, 10.1074/jbc.M203215200 · DOI · Paper page
  14. Shimamura, 2003, Angiopoietin-like protein 3, a hepatic secretory factor, activates lipolysis in adipocytes, Biochem. Biophys. Res. Commun., 301, 604, 10.1016/S0006-291X(02)03058-9 · DOI
  15. Ando, 2003, A decreased expression of angiopoietin-like 3 is protective against atherosclerosis in apoE-deficient mice, J. Lipid Res., 44, 1216, 10.1194/jlr.M300031-JLR200 · DOI
  16. Kaplan, 2003, Regulation of the angiopoietin-like protein 3 gene by LXR, J. Lipid Res., 44, 136, 10.1194/jlr.M200367-JLR200 · DOI · Paper page
  17. Inaba, 2003, Angiopoietin-like protein 3 mediates hypertriglyceridemia induced by the liver X receptor, J. Biol. Chem., 278, 21344, 10.1074/jbc.M213202200 · DOI
  18. Muurling, 2003, Rosiglitazone improves muscle insulin sensitivity, irrespective of increased triglyceride content, in ob/ob mice, Metabolism, 52, 1078, 10.1016/S0026-0495(03)00109-4 · DOI
  19. Zhang, 1999, Bromocriptine/SKF38393 treatment ameliorates dyslipidemia in ob/ob mice, Metabolism, 48, 1033, 10.1016/S0026-0495(99)90202-0 · DOI
  20. Fujiwara, 1991, Characterization of CS-045, a new oral antidiabetic agent, II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice, Metabolism, 40, 1213, 10.1016/0026-0495(91)90218-L · DOI
  21. Chen, 1996, Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice, Cell, 84, 491, 10.1016/S0092-8674(00)81294-5 · DOI · Paper page
  22. Zhang, 1994, Positional cloning of the mouse obese gene and its human homologue, Nature, 372, 425, 10.1038/372425a0 · DOI · Paper page
  23. Goldberg, 2001, Lipid disorders in type 1 and type 2 diabetes, Clin. Lab. Med., 21, 147
  24. Unger, 2003, Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome, Endocrinology, 144, 5159, 10.1210/en.2003-0870 · DOI
  25. McGarry, 2002, Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes, Diabetes, 51, 7, 10.2337/diabetes.51.1.7 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Shimamura, M., Matsuda, M., Ando, Y., Koishi, R., Yasumo, H., Furukawa, H., & Shimomura, I.
Venue
Biochemical and Biophysical Research Communications
Publisher
Elsevier BV
Published
2004-09
Volume
322
Issue
3
Pages
1080-1085
ISSN
0006-291X
DOI
10.1016/j.bbrc.2004.08.024
Cited by
67
References
2
Language
en
Licence
Funders
  • Naito Foundation
  • Kato Memorial Bioscience Foundation
  • Japan Medical Association
  • Suzuken Memorial Foundation
  • Takeda Medical Research Foundation
  • Japan Society for the Promotion of Science
  • Takeda Science Foundation
  • NOVARTIS Foundation (Japan) for the Promotion of Science
  • Ministry of Education, Culture, Sports, Science and Technology
  • Japan Research Foundation for Clinical Pharmacology
  • Ministry of Health, Labour and Welfare
  • Heiwa Nakajima Foundation
  • Tokyo Biochemical Research Foundation
  • Uehara Memorial Foundation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review